Apoptosis: intrinsic and extrinsic pathways, the caspase cascade, and Bcl-2 family regulation
Anchor (Master): Taylor, R. C., Cullen, S. P. & Martin, S. J. — Nat. Rev. Mol. Cell Biol. 9 (2008) 231-244
Intuition Beginner
Apoptosis is programmed cell death — a cell deliberately dismantles itself when it is damaged, infected, or no longer needed. Every day, billions of your cells undergo apoptosis without you noticing. The process is so orderly that neighboring cells clean up the remains before inflammation can begin. Think of it as a building being taken down piece by piece by a demolition crew, rather than being blown up.
Not all cell death is apoptosis. Necrosis is messy, uncontrolled cell death caused by injury or toxin. A necrotic cell swells, bursts, and spills its contents into surrounding tissue, triggering inflammation. Apoptosis is the opposite: the cell shrinks, its DNA is cut into neat fragments, and it breaks apart into small membrane-bound packets called apoptotic bodies that are swallowed by nearby cells or immune cells. No inflammation, no collateral damage.
Two main pathways trigger apoptosis. The intrinsic pathway fires when the cell detects internal damage — for example, DNA that is beyond repair, or severe oxidative stress. The cell's own mitochondria release a protein called cytochrome c into the cytosol, which sets off a self-destruct cascade. The extrinsic pathway fires when the cell receives a "kill signal" from outside — a neighboring cell or an immune cell sends a death ligand that binds to a death receptor on the cell surface, activating the same demolition machinery from a different entry point.
Visual Beginner
The diagram shows the two apoptosis pathways converging on a common execution machinery. On the left, the intrinsic pathway: cellular stress damages the mitochondrion, causing cytochrome c release; cytochrome c binds Apaf-1 to form the apoptosome, which activates caspase-9. On the right, the extrinsic pathway: a death ligand binds the Fas receptor on the cell surface, recruiting adaptor proteins to form the DISC, which activates caspase-8. Both initiator caspases converge on caspase-3, the executioner that dismantles the cell.
Worked example Beginner
A developing human hand starts out as a paddle-shaped structure with webbing between the fingers. Between weeks 5 and 8 of embryonic development, the cells in the webbing receive apoptotic signals and die. If apoptosis fails in this process, the baby is born with syndactyly — fused fingers or toes. This is a direct demonstration that apoptosis is not just about damage control; it is a normal, essential part of shaping tissues during development.
The sequence works as follows. Growth factors that were keeping the webbing cells alive are withdrawn. Without survival signals, the intrinsic pathway activates. The cells between the finger buds shrink, fragment their DNA, break into apoptotic bodies, and are phagocytosed by neighboring cells. The result: five separate fingers where there was once a paddle. Similar apoptotic sculpting shapes the brain (removing excess neurons), the immune system (eliminating self-reactive lymphocytes), and the reproductive organs.
Check your understanding Beginner
Formal definition Intermediate+
Apoptosis is a genetically programmed form of cell death executed by caspase proteases through two converging signaling pathways: the intrinsic (mitochondrial) pathway activated by intracellular stress, and the extrinsic (death receptor) pathway activated by extracellular death ligands.
The caspase family
Caspases are cysteine proteases that cleave after aspartate residues. They are divided into two functional classes:
Initiator caspases (caspase-2, -8, -9, -10) are activated by proximity-induced dimerization on large signaling platforms (the apoptosome or the DISC). They exist as monomeric procaspases in the cytosol. Dimerization on the activating platform triggers autocatalytic cleavage, generating the active heterotetramer (two large and two small subunits). Initiator caspases have long prodomains containing protein-protein interaction motifs: caspase-8 and -10 contain death effector domains (DEDs), while caspase-9 contains a caspase recruitment domain (CARD).
Executioner caspases (caspase-3, -6, -7) exist as preformed dimers that are activated by cleavage at internal aspartate residues by initiator caspases. Caspase-3 is the primary executioner, responsible for the bulk of proteolytic demolition during apoptosis. It cleaves hundreds of substrates, including:
- Nuclear lamins (A, B, C), causing nuclear envelope breakdown.
- ICAD (inhibitor of caspase-activated DNase), releasing CAD (caspase-activated DNase, also called DFF40), which fragments nuclear DNA into 180 bp intervals — the characteristic "DNA ladder" seen on agarose gels.
- PARP (poly-ADP-ribose polymerase), disabling DNA repair.
- Cytoskeletal proteins ( fodrin, gelsolin), causing membrane blebbing and cell shrinkage.
- Bcl-2 family members, generating positive feedback loops that amplify the death signal.
The intrinsic (mitochondrial) pathway
The intrinsic pathway is triggered by intracellular stress signals: DNA damage (detected by p53), oxidative stress, ER stress, growth factor withdrawal, or developmental cues. The pathway converges on the mitochondrion through the Bcl-2 family of proteins, which regulate mitochondrial outer membrane permeabilization (MOMP).
The Bcl-2 family has three functional subgroups:
Anti-apoptotic proteins (Bcl-2, Bcl-xL, Mcl-1, Bcl-w, A1/Bfl-1) contain four Bcl-2 homology (BH) domains (BH1–BH4). They protect cells by binding and sequestering pro-apoptotic proteins on the mitochondrial outer membrane and other intracellular membranes. Their structure mimics the pore-forming domains of bacterial toxins, but they function primarily by inhibiting Bax/Bak oligomerization.
Pro-apoptotic effectors (Bax, Bak, Bok) contain BH1–BH3 domains. In healthy cells, Bax is cytosolic and monomeric; Bak is mitochondrial and held inactive by anti-apoptotic proteins. Upon activation (triggered by BH3-only proteins or direct binding of activators), Bax translocates to the mitochondrial outer membrane, undergoes a conformational change, inserts into the membrane, and oligomerizes. Bak oligomerizes in place. Bax/Bak oligomers form pores in the mitochondrial outer membrane, releasing cytochrome c, Smac/DIABLO, Omi/HtrA2, and other intermembrane space proteins.
BH3-only proteins (Bid, Bim, Puma, Noxa, Bad, Bmf, Hrk, Bik) contain only the BH3 domain. They are the stress sensors that initiate the intrinsic pathway. They fall into two functional classes:
- Activators (Bid, Bim, Puma) bind directly to Bax and Bak, inducing the conformational change that triggers oligomerization. They can also be classified as "direct activators."
- Sensitizers (Bad, Noxa, Bmf, Hrk, Bik) bind to anti-apoptotic proteins (Bcl-2, Bcl-xL, Mcl-1) and displace sequestered activators and effectors, freeing them to act. They do not directly activate Bax/Bak.
This distinction — activators versus sensitizers (also called "derepressors" or "indirect activators") — is supported by binding studies and functional assays, though the classification of individual BH3-only proteins remains an active area of research (some proteins, like Puma, may function in both roles).
MOMP and the apoptosome. Once Bax/Bak pores open the mitochondrial outer membrane, cytochrome c is released into the cytosol. Cytochrome c binds Apaf-1 (apoptotic protease-activating factor 1) in the presence of dATP/ATP. Apaf-1 undergoes a conformational change, exposing its CARD domain and oligomerizing into a heptameric wheel-shaped structure called the apoptosome. The apoptosome recruits seven procaspase-9 molecules through CARD-CARD interactions. The proximity of procaspase-9 molecules on the apoptosome induces their dimerization and activation. Active caspase-9 then cleaves and activates caspase-3, initiating the execution phase.
IAP antagonism. Inhibitor of apoptosis proteins (IAPs), particularly XIAP (X-linked IAP), bind to and inhibit active caspases-3, -7, and -9. XIAP directly blocks the active sites of caspase-3 and -7 and prevents caspase-9 dimerization. To overcome this brake, mitochondria co-release Smac/DIABLO and Omi/HtrA2 alongside cytochrome c. Smac binds XIAP through its AVPI N-terminal tetrapeptide motif, displacing XIAP from caspases and relieving inhibition. This ensures that the caspase cascade proceeds once MOMP has occurred.
The extrinsic (death receptor) pathway
The extrinsic pathway is triggered by extracellular death ligands binding to death receptors on the cell surface. The best-characterized death receptors are members of the TNF receptor superfamily:
Fas (CD95/APO-1). When Fas ligand (FasL) binds Fas, three Fas receptors trimerize. The intracellular death domain (DD) of each receptor recruits the adaptor protein FADD (Fas-associated death domain protein) through homotypic DD-DD interactions. FADD then recruits procaspase-8 (and procaspase-10) through DED-DED interactions, forming the death-inducing signaling complex (DISC). Procaspase-8 molecules are brought into close proximity on the DISC, inducing dimerization and autocatalytic activation. Active caspase-8 directly cleaves and activates caspase-3, bypassing the mitochondrion.
Type I versus Type II cells. In some cells (Type I), the DISC generates enough caspase-8 to directly activate caspase-3 without mitochondrial amplification. In other cells (Type II), DISC-produced caspase-8 is insufficient and must be amplified through the intrinsic pathway: caspase-8 cleaves the BH3-only protein Bid to generate tBid (truncated Bid), which translocates to mitochondria, activates Bax/Bak, and triggers MOMP. The mitochondrial amplification loop ensures sufficient caspase-3 activation to complete apoptosis. The Type I/II distinction was first described in Jurkat (Type II) and SKW6.4 (Type I) lymphocyte cell lines.
TNF receptor 1 (TNFR1). TNF-alpha binding to TNFR1 produces a more complex outcome. The initial signaling complex (Complex I) recruits TRADD, RIPK1, TRAF2, and cIAP1/2, and typically activates NF-kB transcription factors that promote cell survival through upregulation of anti-apoptotic genes (including Bcl-2 family members and c-FLIP). If NF-kB signaling fails or is insufficient, Complex I converts to a cytosolic death complex (Complex II, also called the ripoptosome) that recruits FADD and caspase-8, triggering apoptosis. If caspase-8 is inhibited, RIPK1 and RIPK3 form the necrosome and execute necroptosis (discussed in the master section).
TRAIL receptors (DR4/DR5). TRAIL (TNF-related apoptosis-inducing ligand) binds DR4 and DR5, triggering DISC formation through the same FADD-caspase-8 pathway as Fas. TRAIL has attracted therapeutic interest because it selectively kills cancer cells while sparing most normal cells, although resistance mechanisms in tumors have limited clinical efficacy.
Counterexamples to common slips
Apoptosis and necrosis are the only forms of cell death. Cells can also die by necroptosis (programmed necrosis mediated by RIPK1/RIPK3/MLKL), pyroptosis (inflammatory cell death mediated by gasdermin D), ferroptosis (iron-dependent lipid peroxidation), and autophagic cell death. These are discussed in the master section.
All Bcl-2 family members are anti-apoptotic. The Bcl-2 family includes both anti-apoptotic members (Bcl-2, Bcl-xL) and pro-apoptotic members (Bax, Bak, the BH3-only proteins). The balance between these opposing factions determines cell fate.
Caspase activation always means apoptosis. Caspase-1 is activated by inflammasomes and mediates pyroptosis, not apoptosis. Caspase-8 has non-apoptotic roles in signaling. Caspase-14 is involved in keratinocyte differentiation.
Key mechanism Intermediate+
Mechanism: Bax/Bak-mediated MOMP as the point of no return.
MOMP is the commitment step in intrinsic pathway apoptosis. Once sufficient Bax/Bak pores have formed, cytochrome c release is irreversible and cell death is inevitable, even if the upstream death signal is removed. The mechanism proceeds through defined steps:
Step 1: Bax activation. In healthy cells, Bax is cytosolic, monomeric, and autoinhibited. Its C-terminal transmembrane helix (alpha-9) is tucked into the hydrophobic groove formed by BH1–BH3 domains. Activation begins when an activator BH3-only protein (tBid or Bim) binds the canonical hydrophobic groove of Bax. This displaces the alpha-9 helix, exposing the transmembrane anchor and triggering a large conformational change in which the alpha-1/alpha-2 helices swing away from the core bundle.
Step 2: Mitochondrial translocation and insertion. The exposed alpha-9 helix inserts into the mitochondrial outer membrane, anchoring Bax. A second conformational change exposes the BH3 domain of Bax, which is now available to recruit additional Bax molecules.
Step 3: Oligomerization. Activated Bax molecules dimerize through reciprocal BH3
Step 4: Cytochrome c release. Bax/Bak pores are large enough (estimated 1–20 nm diameter) to allow passage of cytochrome c (roughly 3 nm diameter) and other intermembrane space proteins. In some models, Bax/Bak also cause mitochondrial outer membrane rupture or form lipidic pores by thinning the membrane. The release is typically all-or-nothing at the level of an individual mitochondrion: a mitochondrion either retains all its cytochrome c or loses it completely, reflecting the bistable nature of MOMP.
Step 5: Feedback amplification. Caspase-3, once activated by the apoptosome-caspase-9 axis, cleaves Bid to generate more tBid, which activates more Bax/Bak, releasing more cytochrome c and amplifying the signal. This positive feedback loop ensures that once MOMP passes a threshold, the cell is irreversibly committed to death. The feedback also explains why caspase inhibitors can delay but not prevent cell death after MOMP: the loss of mitochondrial function (outer membrane permeabilization, loss of membrane potential) is itself lethal.
The role of Bak. Bak is structurally and functionally analogous to Bax but is constitutively anchored in the mitochondrial outer membrane via its C-terminal transmembrane helix. In healthy cells, Bak is held inactive by anti-apoptotic proteins (Mcl-1, Bcl-xL). When BH3-only sensitizers displace Bak from its anti-apoptotic guardians, Bak undergoes the same conformational activation and oligomerization as Bax. Cells deficient in both Bax and Bak are highly resistant to intrinsic pathway apoptosis, while deficiency in either alone is partially protective — demonstrating that Bax and Bak serve redundant but essential functions.
Exercises Intermediate+
Regulated cell death beyond apoptosis, BH3 profiling, and therapeutic targeting Master
Caspase-independent cell death
Not all apoptotic cell death requires caspases. When caspases are inhibited (experimentally by zVAD-fmk, or pathologically by viral serpins or IAP overexpression), cells can still die after MOMP through caspase-independent mechanisms:
AIF (apoptosis-inducing factor). AIF is a mitochondrial flavoprotein normally anchored to the inner mitochondrial membrane. After MOMP, AIF is released (its mechanism of release from the inner membrane involves calpain cleavage) and translocates to the nucleus, where it induces large-scale DNA fragmentation (~50 kb fragments) independent of CAD. AIF-mediated DNA fragmentation produces a pattern distinct from the 180 bp ladder of caspase-dependent apoptosis.
Endonuclease G. Another mitochondrial intermembrane space protein released after MOMP. Endonuclease G translocates to the nucleus and generates oligonucleosomal DNA fragments, similar to CAD but caspase-independent. Endonuclease G and AIF may cooperate in caspase-independent nuclear DNA degradation.
Caspase-independent cell death is slower than caspase-dependent apoptosis (hours to days rather than minutes to hours) and may produce morphological features intermediate between apoptosis and necrosis.
Necroptosis: programmed necrosis
Necroptosis is a form of regulated necrosis mediated by the RIPK1–RIPK3–MLKL axis. It is triggered when caspase-8 is inhibited or absent, converting a pro-survival/pro-apoptotic signal into a pro-necrotic one.
Mechanism. Under normal conditions, TNF-alpha binding to TNFR1 activates NF-kB (survival) or, if NF-kB fails, caspase-8-mediated apoptosis. When caspase-8 is inhibited (by viral inhibitors, zVAD-fmk, or physiological regulation), RIPK1 and RIPK3 interact through their RIP homotypic interaction motif (RHIM) domains, forming the necrosome. RIPK3 autophosphorylates and then phosphorylates MLKL (mixed lineage kinase domain-like protein). Phosphorylated MLKL oligomerizes and translocates to the plasma membrane, where it forms pores that disrupt membrane integrity. The cell swells and bursts, releasing damage-associated molecular patterns (DAMPs) that trigger inflammation.
cFLIP as the switch. cFLIP (cellular FLICE-inhibitory protein) is a catalytically inactive caspase-8 homolog that forms heterodimers with caspase-8. The cFLIP/caspase-8 heterodimer retains enzymatic activity (it can cleave RIPK1 and RIPK1, preventing necrosome formation) but cannot process downstream apoptotic substrates. Thus, cFLIP suppresses both apoptosis (by limiting full caspase-8 activation) and necroptosis (by enabling RIPK1/RIPK3 cleavage). The balance between cFLIP isoforms (cFLIP-L, cFLIP-S), caspase-8, and RIPK1 determines whether a cell survives, undergoes apoptosis, or undergoes necroptosis.
Physiological roles. Necroptosis serves as a defense against viral infection: viruses that block caspase-8 to prevent apoptosis inadvertently trigger necroptosis, which eliminates the infected cell while alerting the immune system through inflammation. RIPK3 knockout mice are more susceptible to certain viral infections (vaccinia virus, MCMV). Necroptosis has also been implicated in inflammatory diseases, ischemia-reperfusion injury, and neurodegeneration.
Pyroptosis: inflammatory cell death
Pyroptosis is a form of regulated cell death triggered by the inflammasome and executed by gasdermin D. It is primarily a defense mechanism against intracellular pathogens.
Inflammasome activation. Pattern recognition receptors (NLRP3, NLRC4, AIM2, Pyrin) detect pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) in the cytosol. Upon activation, these sensors recruit the adaptor ASC (apoptosis-associated speck-like protein containing a CARD) and procaspase-1, forming the inflammasome. Procaspase-1 is activated by proximity-induced autocleavage.
Gasdermin D pore formation. Active caspase-1 cleaves gasdermin D into an N-terminal fragment (GSDM-NT) and a C-terminal fragment. GSDM-NT oligomerizes and inserts into the plasma membrane, forming large pores (10–20 nm). These pores disrupt ion gradients, cause water influx and cell swelling, and allow release of mature IL-1beta and IL-18 (which are also cleaved from pro-forms by caspase-1). The cell undergoes membrane rupture and releases its contents, provoking a potent inflammatory response.
Pyroptosis is morphologically distinct from apoptosis (cell swelling and rupture, not shrinkage and fragmentation) and is mediated by caspase-1 (not caspases-3/7/8/9). The gasdermin family includes additional members (gasdermin A, B, C, E) that may be cleaved by other proteases to execute cell death in specific tissues.
Ferroptosis
Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation. It is morphologically, genetically, and biochemically distinct from apoptosis, necroptosis, and pyroptosis.
Mechanism. Ferroptosis occurs when the cellular antioxidant defenses fail to prevent accumulation of lipid peroxides in cellular membranes. The key defense is the GPX4 (glutathione peroxidase 4) enzyme, which uses glutathione (GSH) to reduce lipid hydroperoxides to non-toxic alcohols. When GPX4 activity is lost (through GSH depletion, GPX4 inhibition by RSL3, or cystine import blockade by erastin), lipid peroxides accumulate in a chain reaction catalyzed by iron (Fenton chemistry). The peroxidized lipids destabilize the plasma membrane, causing cell rupture.
Regulation. The cystine/glutamate antiporter system xc- imports cystine, which is reduced to cysteine for glutathione synthesis. Inhibiting system xc- (by erastin or sulfasalazine) depletes GSH and triggers ferroptosis. The transcription factor NRF2 upregulates antioxidant genes (including GPX4, SLC7A11) as a counter-defense. Ferroptosis has been implicated in neurodegeneration (GPX4 knockout in neurons causes rapid degeneration), cancer (some tumors are ferroptosis-sensitive), and ischemia-reperfusion injury.
Autophagic cell death
Autophagy is primarily a survival mechanism (recycling cellular components during starvation), but excessive or dysregulated autophagy can cause cell death. Autophagic cell death (also called type II programmed cell death) is defined morphologically by massive autophagic vacuolization of the cytoplasm without the features of apoptosis. Whether autophagy directly executes cell death or merely accompanies it remains debated. Genetic studies in Drosophila (where autophagic cell death is well-documented in salivary gland degradation during metamorphosis) and in mammalian cells (where autophagy inhibition can paradoxically promote apoptosis) suggest context-dependent roles.
BH3 profiling and precision cancer therapy
BH3 profiling is a functional assay developed by Anthony Letai and colleagues that measures how "primed" a cancer cell is for apoptosis — that is, how close the cell is to the apoptotic threshold.
Method. Isolated mitochondria from tumor cells are exposed to synthetic BH3 peptides from different BH3-only proteins. Each BH3 peptide has a characteristic binding profile: Bad peptide binds Bcl-2 and Bcl-xL; HRK peptide binds Bcl-xL; Noxa peptide binds Mcl-1 and A1; Bim and Puma peptides bind all anti-apoptotic proteins and can directly activate Bax/Bak. The amount of cytochrome c released in response to each peptide reveals which anti-apoptotic proteins the tumor depends on.
Clinical application. If a tumor's mitochondria release cytochrome c in response to the Bad BH3 peptide, the tumor is dependent on Bcl-2 for survival and should be sensitive to venetoclax (a Bcl-2 inhibitor). If the tumor responds to the Noxa peptide instead, it depends on Mcl-1 and would be a candidate for Mcl-1 inhibitors (such as S63845). BH3 profiling has been used prospectively to identify CLL patients who will respond to venetoclax and to guide combination therapies in acute myeloid leukemia (AML).
p53-mediated apoptosis
The tumor suppressor p53 activates apoptosis through both transcription-dependent and transcription-independent mechanisms.
Transcriptional activation. p53 transactivates the genes encoding Puma, Noxa, Bax, and other pro-apoptotic proteins. Puma is the most critical transcriptional target: Puma knockout phenocopies p53 loss for apoptosis in several contexts (including DNA damage-induced death of thymocytes and intestinal crypt cells), while Noxa contributes to apoptosis in specific cell types and in response to particular stresses (proteasome inhibitors, glucose deprivation).
Transcription-independent mechanism. A fraction of stabilized p53 protein translocates to the mitochondria following severe DNA damage. At the mitochondria, p53 can directly activate Bax by binding its BH3 domain, or it can bind anti-apoptotic Bcl-2 and Bcl-xL, displacing sequestered pro-apoptotic proteins. This direct mitochondrial action of p53 provides a rapid apoptosis trigger that does not require new gene expression.
Fas mutations and autoimmune lymphoproliferative syndrome (ALPS)
Autoimmune lymphoproliferative syndrome (ALPS) is a genetic disorder caused by mutations in the Fas death receptor pathway. The most common form (ALPS-FAS, Type Ia) involves heterozygous mutations in the FAS gene (encoding CD95/APO-1). The mutant Fas receptor exerts a dominant-negative effect by incorporating into Fas trimers and preventing DISC formation, even in the presence of one wild-type allele.
Patients with ALPS develop chronic lymphadenopathy, splenomegaly, and autoimmune cytopenias (especially autoimmune hemolytic anemia and immune thrombocytopenia). The disease mechanism is a failure of activation-induced cell death (AICD): activated T lymphocytes that should be eliminated by Fas-mediated apoptosis after an immune response persists and accumulate, producing the enlarged lymph nodes and spleen seen in ALPS. The double-negative T cells (CD3+ CD4- CD8-) that accumulate in ALPS patients are a diagnostic hallmark.
ALPS can also be caused by mutations in FASLG (encoding Fas ligand, ALPS-FASLG, Type Ib), CASP10 (encoding caspase-10, ALPS-CASP10, Type IIa), and rarely CASP8. These genetic findings confirm the essential role of the Fas pathway in maintaining immune homeostasis by eliminating self-reactive and chronically activated lymphocytes.
FLIP proteins: regulators of life and death at the DISC
cFLIP (cellular FLICE-like inhibitory protein) exists as two major splice variants: cFLIP-L (long, 55 kDa) and cFLIP-S (short, 26 kDa). Both contain two DED domains that allow recruitment to the DISC, but neither has a functional caspase domain.
cFLIP-L at low concentrations can promote caspase-8 activation at the DISC (the cFLIP-L/caspase-8 heterodimer is enzymatically active but has altered substrate specificity). At high concentrations, cFLIP-L competes with caspase-8 for DISC binding and inhibits apoptosis. This concentration-dependent dual role makes cFLIP-L a rheostat rather than a simple on/off switch.
cFLIP-S is a pure inhibitor: it displaces caspase-8 from the DISC and prevents its activation. cFLIP-S expression is induced by NF-kB signaling, creating a survival feedback loop downstream of TNFR1 and other receptors.
Both cFLIP isoforms suppress necroptosis by enabling caspase-8-mediated cleavage of RIPK1 and RIPK3 at the DISC or related complexes. Loss of cFLIP (or combined loss of cFLIP and caspase-8) unleashes necroptosis, which is lethal during embryonic development — caspase-8 knockout mice die embryonically from uncontrolled necroptosis, and this lethality is rescued by RIPK3 knockout.
Connections Master
Cell cycle and mitosis
17.08.01. The cell cycle and apoptosis are opposing fates: a cell that cannot repair DNA damage or that fails spindle checkpoint surveillance is diverted from proliferation into apoptosis. p53 is the central node connecting cell cycle arrest (via p21) to apoptosis (via Puma, Noxa, Bax transcription). The decision between arrest-repair and death is influenced by the severity and persistence of the damage signal.Cyclin-CDK regulation
17.08.02pending. CDK activity influences apoptotic sensitivity. CDK1-cyclin B1 can phosphorylate Bcl-2 and Bcl-xL during mitosis, reducing their anti-apoptotic activity and making mitotic cells more vulnerable to death signals. This connection explains why cells with mitotic defects (lagging chromosomes, merotelic attachments) are preferentially eliminated by apoptosis.DNA damage response
17.06.02pending. The DNA damage response activates p53, which transcriptionally induces Puma, Noxa, and Bax. Severe or irreparable DNA damage (persistent gamma-H2AX foci, unrepaired double-strand breaks) shifts p53 activity from cell cycle arrest toward apoptosis. ATM and ATR kinases, which detect double-strand breaks and replication stress respectively, phosphorylate and stabilize p53.Immune system. Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells kill target cells using two mechanisms that converge on apoptosis: (a) release of perforin (which forms pores in the target membrane) and granzyme B (a serine protease that directly cleaves and activates caspases-3 and -7 and Bid); (b) expression of Fas ligand, which triggers the extrinsic pathway. Immune privilege sites (eye, testis) express Fas ligand to kill infiltrating lymphocytes and prevent immune-mediated damage.
Cancer biology. Evasion of apoptosis is one of the original hallmarks of cancer (Hanahan and Weinberg, 2000). Tumors disable apoptosis through multiple mechanisms: Bcl-2 overexpression (follicular lymphoma), p53 mutation (over 50% of human cancers), Fas downregulation, cFLIP overexpression, and IAP upregulation (survivin/BIRC5 in many tumors). Therapeutic strategies targeting these defenses include venetoclax (Bcl-2 inhibitor), navitoclax (Bcl-2/Bcl-xL inhibitor), and Smac mimetics (IAP antagonists).
Mathematical modeling. The caspase cascade has been modeled as an amplifying proteolytic network with switch-like (ultrasensitive) behavior. The Bcl-2 family interaction network has been formalized as a system of competing binding reactions with a bistable steady-state: the cell is either alive (anti-apoptotic proteins dominant) or dead (Bax/Bak active), with no stable intermediate. These models connect apoptosis to dynamical systems theory and bifurcation analysis.
Historical notes Master
The concept of programmed cell death was first described by Carl Vogt in 1842, who observed that certain cells in the developing frog notochord degenerate and disappear during normal embryogenesis. The phenomenon was periodically rediscovered — by Walther Flemming (1885, who described chromatin condensation in dying cells), Ludvig Gräper (1914), and Alfred Glücksmann (1951, who catalogued cell death during vertebrate development) — but remained a descriptive curiosity without mechanistic explanation.
The modern era began in 1965, when John Foxton Ross Kerr examined dying hepatocytes in rats with ligated portal veins using electron microscopy. Kerr observed that the dying cells did not swell and burst (as in necrosis) but shrank, condensed their chromatin, and fragmented into membrane-bound bodies that were engulfed by neighboring cells. Kerr, along with Andrew Wyllie and Alastair Currie, published a landmark paper in 1972 naming this process apoptosis (from the Greek for "falling off," as leaves from a tree). The 1972 paper established that apoptosis is a distinct, regulated form of cell death and proposed that it plays a role in both normal physiology and disease.
The genetic basis of programmed cell death was discovered through the nematode Caenorhabditis elegans. John Sulston mapped the complete cell lineage of C. elegans in 1976, showing that exactly 131 of the 1,090 cells generated during hermaphrodite development undergo programmed death at stereotyped times and positions. Robert Horvitz, in a systematic genetic screen, identified the genes required for these deaths: ced-3 and ced-4 (required for killing) and ced-9 (which prevents death). He also identified genes required for corpse engulfment (ced-1, ced-2, ced-5, ced-6, ced-7, ced-10) and for DNA degradation (nuc-1). The landmark finding was that ced-3 encodes a cysteine protease — the first caspase. Ced-9 is the C. elegans homolog of Bcl-2. Ced-4 is the homolog of Apaf-1. Horvitz and Sulston shared the 2002 Nobel Prize with Sydney Brenner for this work.
The mammalian connection was forged in parallel. The BCL2 gene was cloned from the t(14;18) translocation breakpoint in follicular lymphoma by Tsujimoto and Croce (1985) and by Bakhshi and colleagues (1985). Initially assumed to be a proliferative oncogene (like MYC or RAS), Bcl-2 was shown by Vaux, Cory, and Adams (1988) to instead inhibit cell death — the first "anti-apoptotic" oncogene. When Bcl-2 was expressed in B lymphocytes, the cells accumulated but did not proliferate faster, producing a phenotype resembling follicular lymphoma. This established that cancer can arise not only from accelerated proliferation but also from blocked cell death.
The mammalian caspases were identified in the 1990s. Caspase-1 (originally called ICE, interleukin-1 beta-converting enzyme) was the first to be cloned (Cerretti et al., 1992; Thornberry et al., 1992) based on its homology to ced-3. The discovery that ICE/ced-3-like proteases mediate apoptosis in mammals came from several groups in 1993–1996, with Junying Yuan's laboratory playing a central role. The name "caspase" was proposed by Alnemri and colleagues in 1996 to unify the nomenclature.
The apoptosome was discovered by Xiaodong Wang's laboratory in 1996–1997. Wang's group fractionated cytosolic extracts from cells induced to undergo apoptosis and identified cytochrome c (which they called Apaf-2) as the factor required for caspase activation in a cell-free system. They then cloned Apaf-1 (Apaf-1 = apoptotic protease activating factor 1) and demonstrated that cytochrome c binding triggers Apaf-1 oligomerization into the apoptosome. These experiments elegantly reconstituted the intrinsic pathway from purified components.
The structural biology of Bcl-2 family proteins was illuminated by several groups. The NMR structure of Bcl-xL (Muchmore et al., 1996) revealed its striking similarity to the pore-forming domains of diphtheria toxin and colicins — a structural homology that predicted the pore-forming ability of Bax and Bak before it was directly demonstrated. The structure of Bax (Suzuki et al., 2000) showed the autoinhibited conformation with alpha-9 tucked into the hydrophobic groove, explaining how activation displaces this helix.
The extrinsic pathway was elucidated through the cloning of the Fas receptor (Itoh et al., 1991; Oehm et al., 1992) and Fas ligand (Suda et al., 1993), followed by the identification of FADD (Chinnaiyan et al., 1995) and caspase-8 as the DISC components (Boldin et al., 1996; Muzio et al., 1996). The autoimmune lymphoproliferative syndrome (ALPS) was defined clinically by Sneller et al. (1992) and linked to Fas mutations by Fisher et al. (1995) and Rieux-Laucat et al. (1995), providing a human genetic confirmation of the Fas pathway's role in immune homeostasis.
The discovery of regulated necrosis (necroptosis) challenged the apoptosis-centric view of programmed cell death. The identification of RIPK3 as the necroptosis kinase (Cho et al., He et al., Zhang et al., all in 2009) and MLKL as the executioner (Sun et al., 2012; Zhao et al., 2012) established necroptosis as a genetically defined death pathway. Similarly, the identification of gasdermin D as the pyroptosis executioner (Shi et al., 2015; Ding et al., 2016) revealed a third regulated death pathway. The recognition that cells have multiple genetically encoded death programs — apoptosis, necroptosis, pyroptosis, ferroptosis, and others — has transformed the field from a binary (apoptosis versus necrosis) to a pluralistic framework.
Bibliography Master
Alberts, B. et al. — Molecular Biology of the Cell, 7th ed. (Garland Science, 2022), Ch. 18 Cell Death and Cell Renewal.
Lodish, H. et al. — Molecular Cell Biology, 9th ed. (W. H. Freeman, 2021), Ch. 21 Cell Death.
Taylor, R. C., Cullen, S. P. & Martin, S. J. — Apoptosis: controlled demolition at the cellular level, Nat. Rev. Mol. Cell Biol. 9 (2008) 231-244.
Horvitz, H. R. — Worms, life, and death, Nobel lecture, ChemBioChem 4 (2003) 694-708.
Kerr, J. F. R., Wyllie, A. H. & Currie, A. R. — Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics, Br. J. Cancer 26 (1972) 239-257.
Vaux, D. L., Cory, S. & Adams, J. M. — Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells, Nature 335 (1988) 440-442.
Li, P. et al. — Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade, Cell 91 (1997) 479-489.
Muchmore, S. W. et al. — X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death, Science 274 (1996) 733-736.
Wei, M. C. et al. — Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death, Science 292 (2001) 727-730.
Deng, J. — How BCL-2 family proteins interact with each other and with other proteins to regulate apoptosis, Apoptosis 26 (2021) 1-2.